子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Selective estrogen receptor modulator containing phenylsulfonyl group | JP2010109009 | 2010-05-11 | JP2010195820A | 2010-09-09 | DALLY ROBERT DEAN; DODGE JEFFREY ALAN; FRANK SCOTT A; JONES SCOTT ALAN; SHEPHERD TIMOTHY ALAN; WALLACE OWEN BRENDAN; FONG KIN CHIU; HUMMEL CONRAD WILSON; LEWIS GEORGE SAL |
| <P>PROBLEM TO BE SOLVED: To provide a selective estrogen receptor modulator or a pharmaceutical acid addition salt thereof. <P>SOLUTION: The invention relates to the selective estrogen receptor modulator of a compound represented by formula (I) or the pharmaceutical acid addition salt thereof. The modulator is useful, for example, for treating endometriosis and/or uterine leiomyoma/uterine myoma. <P>COPYRIGHT: (C)2010,JPO&INPIT | ||||||
| 62 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | EP15806027 | 2015-06-09 | EP3154954A4 | 2018-06-13 | COSFORD NICHOLAS DAVID PETER; RAVEENDRA-PANICKAR DHANYA; SHEFFLER DOUGLAS J |
| Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions. | ||||||
| 63 | ORGANIC ELECTROLUMINESCENT COMPOUND, AND ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | EP15845068.4 | 2015-09-25 | EP3197869A1 | 2017-08-02 | MOON, Doo-Hyeon; YANG, Jeong-Eun; KANG, Hee-Ryong; LIM, Young-Mook; JUN, Ji-Song; AHN, Hee-Choon; HONG, Jin-Ri; LEE, Su-Hyun; KIM, Bitnari; LEE, Tae-Jin |
| The present disclosure relates to an organic electroluminescent compound, and an organic electroluminescent material and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has excellent color purity, solubility, and thermal stability. By comprising the organic electroluminescent compound and the organic electroluminescent material of the present disclosure, an organic electroluminescent device showing low driving voltage, excellent current and power efficiencies, and significantly improved lifespan can be provided. | ||||||
| 64 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | EP12713571.3 | 2012-04-03 | EP2694479A1 | 2014-02-12 | LI, Wenjie; DE CROOS, Philomen; FANDRICK, Keith, R.; GAO, Joe, Ju; HADDAD, Nizar; LU, Zhi-Hui; QU, Bo; RODRIGUEZ, Sonia; SENANAYAKE, Chris, H.; ZHANG, Yongda; TANG, Wenjun |
| The present invention is directed to an improved process for the preparation of Compounds of Formula (I) or salts thereof which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)- 2-methylquinolin-3-yl)acetic acid or salt thereof which is useful in the treatment of HIV infection. R 4 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n) and (o); and R 6 and R 7 are each independently selected from H, halo and (C 1-6) alkyl. | ||||||
| 65 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | EP03765254.2 | 2003-07-16 | EP1530470B9 | 2010-04-07 | DALLY, Robert, Dean; DODGE, Jeffrey, Alan; FRANK, Scott, Alan; JONES, Scott, Alan; SHEPHERD, Timothy, Alan; WALLACE, Owen, Brendan; FONG, Kin, Chiu; HUMMEL, Conrad, Wilson; LEWIS, Geroge, Sal |
| The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata. | ||||||
| 66 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | EP03765254.2 | 2003-07-16 | EP1530470A1 | 2005-05-18 | DALLY, Robert, Dean; DODGE, Jeffrey, Alan; FRANK, Scott, Alan; JONES, Scott, Alan; SHEPHERD, Timothy, Alan; WALLACE, Owen, Brendan; FONG, Kin, Chiu; HUMMEL, Conrad, Wilson; LEWIS, Geroge, Sal |
| The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata. | ||||||
| 67 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | EP02761567.3 | 2002-09-05 | EP1423381A1 | 2004-06-02 | GUZI, Timothy J.; PARUCH, Kamil; MALLAMS, Alan K.; RIVERA, Jocelyn, D.; DOLL, Ronald, J.; GIRIJAVALLABHAN, Viyyoor, M.; PACHTER, Jonathan; LIU, Yi-Tsung; SAKSENA, Anil, K. |
| There are disclosed compounds of the formula (I), prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17beta-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases. | ||||||
| 68 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | US15697867 | 2017-09-07 | US10131648B2 | 2018-11-20 | Hui Huang; Gee-Hong Kuo; Mark R. Player; Shyh-Ming Yang; Yue-Mei Zhang |
| Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein. | ||||||
| 69 | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof | US15315363 | 2015-06-09 | US09969726B2 | 2018-05-15 | Nicholas David Peter Cosford; Dhanya Raveendra-Panickar; Douglas J. Sheffler |
| Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions. | ||||||
| 70 | 4-methylsulfonyl-substituted piperidine urea compounds | US15003662 | 2016-01-21 | US09925177B2 | 2018-03-27 | Johan Oslob; Danielle Aubele; Jae Kim; Robert McDowell; Yonghong Song; Arvinder Sran; Min Zhong |
| The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease. | ||||||
| 71 | Estrogen receptor modulators and uses thereof | US14972333 | 2015-12-17 | US09845291B2 | 2017-12-19 | Jun Liang; Daniel Fred Ortwine; Xiaojing Wang; Steven P. Govek; Mehmet Kahraman; Johnny Y. Nagasawa; Nicholas D. Smith; Simon Charles Goodacre; Nicholas Charles Ray |
| Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | ||||||
| 72 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | US14877972 | 2015-10-08 | US09790198B2 | 2017-10-17 | Hui Huang; Gee-Hong Kuo; Mark R. Player; Shyh-Ming Yang; Yue-Mei Zhang |
| Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein. | ||||||
| 73 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | US14972333 | 2015-12-17 | US20170197915A9 | 2017-07-13 | Jun Liang; Daniel Fred Ortwine; Xiaojing Wang; Steven P. Govek; Mehmet Kahraman; Johnny Y. Nagasawa; Nicholas D. Smith; Simon Charles Goodacre; Nicholas Charles Ray |
| Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | ||||||
| 74 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | US14877972 | 2015-10-08 | US20160102071A1 | 2016-04-14 | Hui Huang; Gee-Hong Kuo; Mark R. Player; Shyh-Ming Yang; Yue-Mei Zhang |
| Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein. | ||||||
| 75 | PATTERN FORMING METHOD, COMPOUND USED THEREIN, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE, AND ELECTRONIC DEVICE | US14811926 | 2015-07-29 | US20150331314A1 | 2015-11-19 | Shuhei YAMAGUCHI; Takamitsu TOMIGA; Fumihiro YOSHINO; Hajime FURUTANI; Michihiro SHIRAKAWA; Mitsuhiro FUJITA |
| There is provided an actinic ray-sensitive or radiation-sensitive resin composition comprising: (A) a resin having a group capable of decomposing by an action of an acid to produce a polar group, (C1) a compound containing a group capable of generating a first acidic functional group upon irradiation with an actinic ray or radiation and a group capable of generating a second acidic functional group different from the first acidic functional group upon irradiation with an actinic ray or radiation, and (C2) at least one compound containing two or more groups selected from the group consisting of the groups capable of generating the structures represented by the specific formulae upon irradiation with an actinic ray or radiation. | ||||||
| 76 | Arylosulfonamides for the treatment of CNS diseases | US14338704 | 2014-07-23 | US09120767B2 | 2015-09-01 | Marcin Kołaczkowski; Piotr Kowalski; Jolanta Jaśkowska; Monika Marcinkowska; Katarzyna Mitka; Adam Bucki; Anna Wesołowska; Maciej Pawłowski |
| Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system. | ||||||
| 77 | Photoresist composition | US13025876 | 2011-02-11 | US08530137B2 | 2013-09-10 | Tatsuro Masuyama; Satoshi Yamaguchi |
| The present invention provides a photoresist composition having a sulfonium salt comprising an anion represented by the formula (IA): wherein R1 and R2 independently represent a hydrogen atom, a C1-C12 aliphatic hydrocarbon group, a C3-C20 saturated cyclic hydrocarbon group, a C6-C20 aromatic hydrocarbon group or a C7-C21 aralkyl group, and the aliphatic hydrocarbon group, the saturated cyclic hydrocarbon group, the aromatic hydrocarbon group and the aralkyl group can have one or more substituents selected from the group consisting of a hydroxyl group, a cyano group, a fluorine atom, a trifluoromethyl group and a nitro group, and one or more —CH2— in the aliphatic hydrocarbon group can be replaced by —O— or —CO—, or R1 and R2 are bonded each other to form a C4-C20 nitrogen-containing ring together with the nitrogen atom to which they are bonded, an acrylic resin having an acid-labile group and being insoluble or poorly soluble in an aqueous alkali solution but becoming soluble in an aqueous alkali solution by the action of an acid, and an acid generator. | ||||||
| 78 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | US13824066 | 2011-09-16 | US20130172365A1 | 2013-07-04 | Marcin Kolaczkowski; Piotr Kowalski; Jolanta Jaskowska; Monika Marcinkowska; Katarzyna Mitka; Adam Bucki; Anna Wesolowska; Maciej Pawlowski |
| Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system. | ||||||
| 79 | Organic dye used in dye-sensitized solar cell | US12958609 | 2010-12-02 | US07985864B2 | 2011-07-26 | Marappan Velusamy; Koilpitchai R. Justin Thomas; Jiann T'suen Lin; Kuo-Chuan Ho; Ying-Chan Hsu |
| An organic dye used in a dye-sensitized solar cell is described, having general formula (1): D-Sp1-Ch-Sp2-Acc-Y (1) wherein the groups D, Ch, Acc and Y are conjugate with each other, the group D is a donor group, the group Ch is a chromophore rendering low HOMO-LUMO gap or a polyaromatic chromophore, the group Acc is an acceptor group, the group Y is an anchoring group, and each of Sp1 and Sp2 represents a single bond or a spacer group allowing conjugation between the groups D and Ch or between the groups Ch and Acc. | ||||||
| 80 | Organic dye used in dye-sensitized solar cell | US12237014 | 2008-09-24 | US07868189B2 | 2011-01-11 | Koilpitchai R. Justin Thomas; Jiann T'suen Lin; Kuo-Chuan Ho; Ying-Chan Hsu |
| An organic dye used in a dye-sensitized solar cell is described, having general formula (1): D-Sp1-Ch-Sp2-Acc-Y (1) wherein the groups D, Ch, Acc and Y are conjugate with each other, the group D is a donor group, the group Ch is a chromophore rendering low HOMO-LUMO gap or a polyaromatic chromophore, the group Acc is an acceptor group, the group Y is an anchoring group, and each of Sp1 and Sp2 represents a single bond or a spacer group allowing conjugation between the groups D and Ch or between the groups Ch and Acc. | ||||||
QQ群二维码
意见反馈
意见反馈